ATE252913T1 - Vorbeugung einer krankheit mit diabetes charakter - Google Patents

Vorbeugung einer krankheit mit diabetes charakter

Info

Publication number: ATE252913T1
Authority: AT; Austria
Prior art keywords: diabetes; prevention; type disease; type; disease
Prior art date: 1995-06-30

Application number

AT96921919T

Other languages

English (en)

Inventor

Thomas Dyrberg

Anne Worsaae

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-30

Filing date

1996-07-01

Publication date

2003-11-15

1996-07-01 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE252913T1 publication Critical patent/ATE252913T1/de

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000002265 prevention Effects 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
230000002218 hypoglycaemic effect Effects 0.000 abstract 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Zoology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

AT96921919T 1995-06-30 1996-07-01 Vorbeugung einer krankheit mit diabetes charakter ATE252913T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK76595		1995-06-30
PCT/DK1996/000297 WO1997002043A1 (en)	1995-06-30	1996-07-01	Prevention of a disease having the characteristics of diabetes

Publications (1)

Publication Number	Publication Date
ATE252913T1 true ATE252913T1 (de)	2003-11-15

Family

ID=8097303

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96921919T ATE252913T1 (de)	1995-06-30	1996-07-01	Vorbeugung einer krankheit mit diabetes charakter

Country Status (7)

Country	Link
US (3)	US6274549B1 (de)
EP (1)	EP0835129B1 (de)
JP (1)	JPH11509195A (de)
AT (1)	ATE252913T1 (de)
AU (1)	AU6299596A (de)
DE (1)	DE69630527T2 (de)
WO (1)	WO1997002043A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU781405B2 (en) *	1998-02-23	2005-05-19	Neurocrine Biosciences, Inc.	Methods for treatment of diabetes using peptide analogues of insulin
US6562942B1 (en)	1999-02-23	2003-05-13	Neurocrine Biosciences, Inc.	Methods for treatment of diabetes using peptide analogues of insulin
CN1241942C (zh)	1998-02-23	2006-02-15	纽罗克里恩生物科学有限公司	使用胰岛素的肽类似物治疗糖尿病的方法
JPH11353404A (ja) *	1998-06-11	1999-12-24	Hitachi Ltd	電子カルテシステム
EP2033662B1 (de)	2004-01-21	2012-10-17	Novo Nordisk Health Care AG	Transglutaminase vermittelte konjugation von peptiden.
CN101027318B (zh)	2004-07-19	2016-05-25	比奥孔有限公司	胰岛素-低聚物共轭物，制剂及其用途
US9241908B2 (en)	2007-10-16	2016-01-26	Biocon Limited	Orally administrable solid pharmaceutical composition and a process thereof
HUE032284T2 (en)	2008-03-18	2017-09-28	Novo Nordisk As	Protease-stabilized, acylated insulin analogues
BR112015015258A2 (pt)	2012-12-24	2017-09-26	Neurogastrx Inc	métodos para tratar distúrbios do trato gastrintestinal
WO2015200369A1 (en)	2014-06-24	2015-12-30	Neurogastrx, Inc.	Prodrugs of metopimazine
ES2886837T3 (es)	2016-12-16	2021-12-21	Novo Nordisk As	Composiciones farmacéuticas que contienen insulina
US10836757B1 (en)	2020-04-02	2020-11-17	Neurogastrx, Inc.	Polymorphic forms of metopimazine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5422339A (en) *	1991-03-19	1995-06-06	Joslin Diabetes Center, Inc.	Peptides having insulin autoantibody but not insulin receptor binding capacity
US5891435A (en) *	1993-04-16	1999-04-06	Research Corporation Technologies, Inc.	Methods and compositions for delaying or preventing the onset of autoimmune disease
US5725860A (en) *	1994-03-07	1998-03-10	Auckland Uniservices Limited	Method for reducing the risk of developing diabetes
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
WO1997009061A1 (en)	1995-09-06	1997-03-13	Alexion Pharmaceuticals, Inc.	Treatment of diabetes via administration of hormonally ineffective insulin

1996
- 1996-07-01 EP EP96921919A patent/EP0835129B1/de not_active Expired - Lifetime
- 1996-07-01 AT AT96921919T patent/ATE252913T1/de not_active IP Right Cessation
- 1996-07-01 WO PCT/DK1996/000297 patent/WO1997002043A1/en not_active Ceased
- 1996-07-01 DE DE69630527T patent/DE69630527T2/de not_active Expired - Fee Related
- 1996-07-01 US US09/319,138 patent/US6274549B1/en not_active Expired - Fee Related
- 1996-07-01 JP JP9504729A patent/JPH11509195A/ja active Pending
- 1996-07-01 AU AU62995/96A patent/AU6299596A/en not_active Abandoned
2001
- 2001-05-02 US US09/847,623 patent/US20010021696A1/en not_active Abandoned
- 2001-06-01 US US09/872,923 patent/US20010041669A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20010041669A1 (en)	2001-11-15
DE69630527T2 (de)	2004-08-05
US6274549B1 (en)	2001-08-14
WO1997002043A1 (en)	1997-01-23
DE69630527D1 (de)	2003-12-04
EP0835129A1 (de)	1998-04-15
EP0835129B1 (de)	2003-10-29
US20010021696A1 (en)	2001-09-13
AU6299596A (en)	1997-02-05
JPH11509195A (ja)	1999-08-17

Similar Documents

Publication	Publication Date	Title
FI904414A7 (fi)	1990-09-07	Tiatsolidiinidioni-hypoglykeemisesti vaikuttavat aineet
DE69630527D1 (de)	2003-12-04	Vorbeugung einer krankheit mit diabetes charakter
EP0236684A3 (en)	1988-12-14	Galanthamine or analogues thereof for treating alzheimer's disease
DE3889536D1 (de)	1994-06-16	Behandlung von krebs mit somatostatin und mit analogen davon.
DE69132035D1 (en)	2000-04-13	Bandage
SE9500639L (sv)	1996-08-22	Assistansbordspåse
TR200000134T2 (tr)	2000-09-21	Tiazolidinedion, ensülin salgılatıcısı ve biguanid ile diabetin (şeker hastalığının) tedavisi.
ATE258797T1 (de)	2004-02-15	Verwendung von amifostin
BR9810444A (pt)	2000-09-05	Tratamento de diabete com rosiglitazona e insulina
DE68907635D1 (de)	1993-08-26	Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
DE69116224D1 (de)	1996-02-22	Behandlung von intraokularem Druck mit einer synergischen Kombination
ATE117208T1 (de)	1995-02-15	Behandlung von intraokularem druck mit einer ophthalmischen synergistischen kombination.
DE68904794D1 (de)	1993-03-25	Oesenteil fuer einen haken-oesen-verschluss.
EP1123100A4 (de)	2001-12-19	Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta-estern desselben
DE69100171D1 (de)	1993-08-19	Synergistische kombination zur ophthalmischen verwendung.
ES521445A0 (es)	1984-11-01	Un procedimiento para preparar 6-metil-tio-espiro-ckroman-4,4' imidazolin-2',5'-diona.
FI972674L (fi)	1997-06-19	3,3-(disubstituoituja)sykloheksan-1-olimonomeerejä ja vastaavia yhdisteitä
BR9703451C2 (pt)	2004-10-19	Composto natural para o tratamento de diabete, câncer e etc...
ATE198476T1 (de)	2001-01-15	Alternative kristallform von tazofelon ((+,-)-5- ((3,5-bis(1,1-dimethylethyl)-4- hydroxyphenyl)methyl)-4-thiazolidinon)
ATE100697T1 (de)	1994-02-15	System und verfahren zum zusammenbau einer orthese.
IT8603418A1 (it)	1987-11-16	Calzatura anatomica per la prevenzione e la correzione dell'alluce valgo.
IT8603418A0 (it)	1986-05-16	Calzatura anatomica per la prevenzione e la correzione dell'alluce valgo
BR9401034C1 (pt)	2000-05-23	Dispositivo de desarme automático para hastes subsoladoras
ES1037506U (es)	1998-03-01	Pasador perfeccionado para cordones de calzado.
DE68902456D1 (de)	1992-09-17	Verschluss fuer uhrarmbaender.

Legal Events

Date	Code	Title	Description
2004-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties